Company intelligence / Profile preview
Kyowa Kirin
Chiyoda-ku, Tokyo, Japankyowakirin.com ↗
- Ownership
- Public · 4151
- Employees
- ~5669
- Development stage
- Commercial
01
Overview
Kyowa Kirin has a strong portfolio of commercialized drugs and a robust pipeline focusing on innovative therapies.
- Therapeutic areas
- OncologyHematologyEndocrinologyRare Diseases
- Modalities
- Monoclonal Antibodies (mAbs)Small MoleculesGene Therapy
- Industry
- Biotech
02
Drug pipeline
76 assets75 more assets in the full pipeline.
03
Partnerships
SynaffixAlphaMeld Corporation
04
Financials
- Market cap
- $8B
- Total revenue
- $3.1B
- Enterprise value
- $6.6B
Beyond the preview
Go deeper on Kyowa Kirin.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kyowa Kirin.